pharmanet®

Experience You Can Trust

PharmaNet Lecture Series

Type 1 Diabetes

Ron Innerfield, MD, FACE

Goals

To present a broad, low-power overview of type 1 diabetes with selected views in varied magnification and sundry light

pharmanet®

Kylie Middleton Calls her GP Out

16 years old single mother
White North European

5 episodes of thrush infection in 3 weeks
dry mouth
depressed fed up
losing weight

tummy pain for 12 hours
now vomiting
feeling breathless

What is Diabetes Mellitus?

The

Final Common

Pathway of Expression of

Elevated Blood Glucose (Hyperglycemia) ***where***

Small Vessel Complications =

Σ([blood glucose],time)

pharmanet®

Normal Retinal Fundus



Increased Glycosylation



Diabetic Nephropathy



Diagnosis of Diabetes Mellitus

high plasma glucose twice
OR
high plasma glucose + typical symptoms

Different types of diabetes

type 1
type 2
gestational diabetes
other types

The Clinical Spectrum of Diabetes Mellitus

Type 1 autoimmune destruction of insulin producing pancreatic beta islet cells
UK prevalence 0.5% and rising

Type 2 insulin resistant condition with inadequate insulin secretion
UK prevalence 4% (2% overt) and rising

Gestational diabetes

Other types
pancreatic disease
endocrine disease
drug induced
specific genetic disorders

Type 1 Diabetes Mellitus

- usually autoimmune destruction of insulin-producing pancreatic islet β cells over months
- absolute insulin deficiency
- rapid presentation with
  thirst, polyuria, weight loss, blurred vision
  thrush, lethargy, dizziness
- usually thin and ketotic at presentation

Type 1 Diabetes in 1922

Figure 2 A 3-year-old child with type 1 diabetes mellitus, photographed in 1922 before insulin treatment was available.

Stages in the Development of Type 1 Diabetes



J. Skyler

Normal Pancreas Histology



pharmanet®

Normal Islet



pharmanet®

What's What and Where in the Islet?



pharmanet®

Progression to Diabetes vs Number of Autoantibodies (GAD, ICA512, Insulin)



3 Ab	n = 41	17	8	1		
2 Abs	n = 44	27	15	4	2	1
1 Abs	n = 93	23	14	10	6	4

pharmanet®

Insulitis



pharmanet®

Antigen presentation



Antigen presentation-2



Representation of T-cell activation – Schematic representation of initiation of the immunologic response to an antigen. The antigen binds to a groove in MHC class II molecules on antigen-presenting cells (APCs, such as macrophages). This binding allows the antigen to be presented to antigen receptors on autoreactive CD4 inducer or helper T cells which, in type 1 diabetes mellitus, initiate autoimmune injury to the pancreatic ß-cells. In addition, the respective binding of B7 proteins and LFA-3 (lymphocyte functional antigen-3) on APCs to CD28 and CD2 on T cells are important **costimulatory pathways** that further increase T-cell activation. Other molecules also can participate in the immune response, such as the binding of interleukin-2 to its receptor (IL-2R).

Gene Frequencies - DQ-ß and DM-1



Association of type 1 diabetes with diabetogenic genes Direct correlation in different populations between the gene frequency of "diabetogenic" HLA-DQß genotypes (which lack aspartate at position 57 on the beta chain) and the predicted and observed incidence of type 1 diabetes mellitus (per 100,000 population). (Data from Dorman, JS, LaPorte, RE, Stone, RA, Trucco, M, Proc Natl Acad Sci USA 1990; 87:7370.)

Antigen presentation-3



Antigen presentation-4

Asp^{57} on the DQ$_{ß}$ chain forms a salt bridge with Arg on the DQ$_{α}$ chain and confers protection against insulitis







IDDM usually associates with a Ser^{57}, Val^{57}, or Ala^{57} which fails to form a salt bridge with the Arg on the DQ$_{α\ chain}$

Lack of Progression to DM of ICA+ 0602+ Relatives



pharmanet®

Type 1 Diabetes Data

30% identical twin concordance rate

- prevalence increasing currently 0.5%
- *in Europe prevalence increases toward north pole*
- onset in childhood increasing
- childhood diabetes more prevalent in rural areas

Geography of DM-1

pharmanet®

What Characterizes the *Spectrum* of Type 1 Diabetes?

- **Incomplete penetrance**
- ***Nordic predominance***
- **Increased *glyco*sylation**

- Increased *freezing point* depression?

pharmanet®

Glycosylation and *Arctic* Survival

- ***Annu. Rev. Physiol.*** **[2001]** 63**:35990**
- *ANTIFREEZE PROTEINS OF TELEOST FISHES*
- **Garth L Fletcher, Choy L Hew, and Peter L Davies 1Ocean Sciences Centre, Memorial University of Newfoundland, St. John's, Newfoundland A1C 5S7, Canada**

"*The discovery of antifreeze glycoproteins (AFGPs)* [was] *in the blood plasma of Antarctic Nototheniids in the late 1960s….*"

pharmanet®

Type 1 Diabetes
What Goes Wrong?



pharmanet®

Intermediary Metabolism

Cytoplasm





Mitochondrion



pharmanet®

Insulin Message

- **Insulin is the major message to the various cells of the body that:-**
  - **The fed state has just been achieved**
  - ***Anabolic*** **functions may occur. i.e.,**
    - **Lipogenesis/Transport/Storage**
    - **Antagonize gluconeogenesis**
    - **Absorb glucose into fat and muscle and liver cells**

Insulin





pharmanet®

Insulin Secretion-1



Insulin Secretion-2

from pancreatic islet cells
secretion requires glucose entry in cells

secretion triggered by
- hyperglycaemia
- vagal stimulation
- leucine / arginine
- free fatty acids & ketones
- sulphonylurea drugs

secretion inhibited by
- catecholamines
- neuropeptide Y
- somatoostatin
- diazoxide
- leptin

secretion enhanced by
- GIP
- glucagon like peptide
- vagal stimulation

Insulin Secretion - 3



pharmanet®

Insulin Secretion-4



SUR-1/Kir6.2

pharmanet®

Normal Glucose Regulation



Insulin Action

binds to cell-surface insulin receptor
activates a protein kinase
leading to downstream intracellular insulin signalling

intracellular actions of insulin stimulate
- nutrient uptake
- biosynthetic processes

glucose uptake enhanced by increasing glucose transporters on the cell surface

Insulin Action-2



pharmanet®

Insulin Action-3



- stimulates glucose uptake
  - esp by fat & muscle
  - increases membrane glucose transporters

- activates glycogen synthesis in muscle
  - ↑glycogen synthase activity
- activates lipogenesis



- phosphorylation of intracellular proteins
- increased DNA & RNA synthesis and cell division

Counter-regulatory hormones

released in response to hypoglycaemia

glucagon
- from pancreatic islet α cells
- acts on ↑ gluconeogenesis & liver
- glycogenolysis

adrenaline
- acts on liver muscle and fat cells
- ↑ glycogenolysis, lipolysis

cortisol
- acts on liver, muscle and fat
- ↑ gluconeogenesis, protein breakdown
- ↓ muscle glucose uptake

growth hormone
- from anterior pituitary
- ↑ lipolysis
- ↓ muscle glucose uptake

Endocrine Causes of Diabetes Mellitus

no insulin production — common

insufficient insulin production
tissue insensitivity to insulin — very common

increased circulating levels of counterregulatory hormones

- excessive growth hormone (acromegaly)
- excessive catecholamines (pheochromocytoma)
- excessive cortisol (Cushing's syndrome)

Very rare

Corticosteroids



pharmanet®

Glycolysis-1$_{Insulin}$



Glycolysis-2$_{Insulin}$



Mitochondrial Metabolism -
The Tricarboxylic Acid Cycle (Krebs)



pharmanet®

Liver and Muscle



Hepatocyte – A Purveyor of Glucose



pharmanet®

Gluconeogenesis-1 counter-regulatory



pharmanet®

Gluconeogenesis-2 counter-regulatory



pharmanet®

Lipogenesis



Lipolysis counter-regulatory



Insulinoprivic or *Counter-Regulatory* Lipolysis



Acetoacetate + Succinyl-CoA <===> Acetoacetyl-CoA + succinate

(ketoacyl-CoA-transferase) **[Liver? Inhibition by Glucagon?]**

pharmanet®

Diabetic Pathophysiology - Liver



pharmanet®

Diabetic Pathophysiology - Muscle



pharmanet®

Diabetic Keto-Acidosis (DKA)



Kylie Middleton Calls her GP Out

16 years old single mother
White North European

5 episodes of thrush infection in 3 weeks
dry mouth
depressed fed up
losing weight

tummy pain for 12 hours
now vomiting
feeling breathless

Type 1 Diabetes in 1923

Figure 2 A 3-year-old child with type I diabetes mellitus, photographed in 1922 before insulin treatment was available.

pharmanet®